New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
08:18 EDTCPHDCepheid Q2 results should beat expectations, says Wedbush
Wedbush thinks the high number of Cepheid's Infinity placements in 4Q13 and Q1 could boost the company's Q2 results. The firm keeps a $58 price target and Outperform rating on the shares.
News For CPHD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
16:09 EDTCPHDCepheid receives FDA emergency use authorization for Xpert Ebola diagnostic test
Cepheid announced it has received Emergency Use Authorization from the FDA for Xpert Ebola, a molecular diagnostic test for Ebola Zaire Virus that delivers results in less than two hours. The test runs on the Cepheid GeneXpert Systems. Xpert Ebola has been authorized by FDA under an Emergency Use Authorization for use by CLIA moderate and high complexity laboratories or similarly qualified non-U.S. laboratories. The test will begin shipping in April. Cepheid's Xpert Ebola has not been FDA cleared or approved, but will remain available in the U.S. as an EUA product as long as the declared emergency remains in effect or it ceases to be authorized by FDA.
March 19, 2015
08:57 EDTCPHDCepheid has a conference call hosted by JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use